Also provided herein are methods for selectively killing senescent cells in a subject who has a senescence associated disease or disorder, which in certain embodiments is not a cancer, and which senolytic agents described herein are administered to the subject in need thereof according to the administration methods described herein. As described herein the senolytic agent is administered for a time sufficient and in an amount sufficient that selectively kills senescent cells. The following are certain embodiments described in greater detail herein. Provided herein are methods for treating senescence-associated diseases by administering a senolytic agent. The present disclosure addresses these needs and offers related advantages. However, identifying and developing treatments of such diseases and conditions by selective elimination of senescent cells has been an arduous undertaking. Given that senescent cells have been causally implicated in certain aspects of age-related decline in health and may contribute to certain diseases, and are also induced as a result of necessary life-preserving chemotherapeutic and radiation treatments, the presence of senescent cells may have deleterious effects to millions of patients worldwide. 20:150-55 (2008)) nevertheless, the presence of senescent cells in an individual may contribute to aging and aging-related dysfunction (see, e.g., Campisi, Cell 120:513-22 (2005)). Senescent cells are believed important to inhibiting proliferation of dysfunctional or damaged cells and particularly to constraining development of malignancy (see, e.g., Campisi, Curr.
Senescent cells accumulate in tissues and organs of individuals as they age and are found at sites of age-related pathologies. The disclosure herein relates generally to methods for treatment and prophylaxis of senescent cell-associated diseases and disorders. 10, 2019, and is being submitted electronically via EFS-Web. The text file is 8 KB, was created on Jul. The name of the text file containing the Sequence Listing is 44237-721-312-Sequence-Listing.txt. The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The government has certain rights in the invention. This invention was made with government support under AG009909, AG017242, AG041122 and AG046061 awarded by the National Institutes of Health. 15/114,762 and PCT/US2015/013387 are hereby incorporated herein by reference in their entirety for all purposes. Provisional Application 61/932,704, filed Jan. Provisional Application 61/932,711, filed Jan. Provisional Application 61/979,911, filed Apr. Provisional Application 62/042,708, filed Aug. Provisional Application 62/044,664, filed Sep. Provisional Application 62/057,820, filed Sep. Provisional Application 62/057,825, filed Sep. Provisional Application 62/057,828, filed Sep. Provisional Application 62/061,627, filed Oct.
Provisional Application 62/061,629, filed Oct. 28, 2015 which claims the priority benefit of U.S. National Stage of PCT/US2015/013387, filed Jan.
0 kommentar(er)
